SLC16A1 and cancer: Lactate transport in cancer cells could also be targeted by direct inhibition of MCTs.202–204 Indeed, the MCT1-specific inhibitor AZD3965 is currently in Phase 1 clinical trial (clinicaltrials.gov identifier: NCT01791595).